A woman in her forties walks into a pharmacy this week and, for the first time, finds a weight-loss prescription she can plausibly afford without dipping into savings. Foundayo, Eli Lilly’s oral orforglipron tablet, costs somewhere between a hundred and a hundred and eighty pounds a month depending on dose and retailer, well under the £330 asked for injectable Mounjaro. She is still unable to obtain it through the NHS. Her local integrated care board runs a tier three weight management service with a waiting list measured in months, if it runs one at all. So she pays. Multiply her by the tens of thousands of people who sit just above what their GP surgery can offer and just below what private <a href="https://healthylife7.com/in-iran-spiraling-health-costs-force-people-to-delay-care/” title=”In Iran, spiraling health costs force people to delay care”>healthcare has always assumed of its customers, and the shape of the problem becomes clear.
The Medicines and Healthcare products Regulatory Agency approved orforglipron on 10 August, making Britain the first country in Europe to license it for both weight management and type 2 diabetes. That regulatory speed has not been matched by commissioning speed. NICE is not expected to publish its verdict on Foundayo for obesity until 18 November, and NHS funding, if it comes at all, will follow months after that. Diabetes prescribing may move faster, since NICE has declined to run a separate appraisal there, judging that its existing GLP-1 class guidance already covers the drug. The result is a medicine now sitting in a strange administrative limbo, licensed everywhere, funded almost nowhere, and priced for the first time within reach of people who have spent years watching GLP-1 treatments as something other patients received.
This matters more than a routine appraisal delay because of what already happens in the space between approval and reimbursement. Eli Lilly is currently pursuing legal action against suppliers it accuses of running an illegal secondary market in its products, and the MHRA seized a quarter of a million pounds of unlicensed weight-loss pens and raw ingredients from a single Northampton factory last year. Pills are, by the pharmacy sector’s own account, easier to counterfeit than injectable pens. Henry Gregg of the National Pharmacy Association welcomed Foundayo’s arrival while pointing directly at the enforcement gap it will widen, and his description of NHS weight management provision as a postcode lottery is not rhetorical inflation. Access via GP referral still depends heavily on where a patient happens to live, which ICB commissions which tier of service, and how stretched that service already is.
What Foundayo does is compress the distance between aspiration and access without closing it. A drug priced close to what a determined patient might scrape together is not the same as a drug that patient can get through legitimate channels, and that near-miss is exactly the condition in which grey markets thrive. Nobody buys counterfeit medicine when the price gap to the real thing is unbridgeable. They buy it when the real thing feels one paycheque away and the legitimate route is slow, opaque or simply unavailable where they live.
For NHS leaders, the practical question is not whether to await NICE’s ruling but whether commissioning variation across ICBs can survive three more months of a private market normalising a treatment the public system has not yet approved. For the MHRA, it is whether enforcement capacity has kept pace with a market growing faster than the licensing pipeline that is meant to police it. For ministers preparing October’s Budget, weight management sits awkwardly between two competing pressures, the fiscal case for cheaper obesity treatment reducing downstream NHS costs, and the immediate reality that funding a national rollout requires money nobody has yet allocated.
None of this is an argument against Foundayo’s approval, which genuinely widens options for patients who could never tolerate an injectable. It is an argument that regulatory speed without commissioning speed creates its own risks, and that the postcode lottery Gregg described will not wait politely for NICE’s November verdict to catch up
